INVERNIZZI PIETRO

Posizione organizzativa:
Ruolo:
Professore ordinario
Settore scientifico disciplinare:
Gastroenterologia (MED/12)
Stanza:
  • U08, Piano: 3, Stanza: 3019
  • U08, Piano: 3, Stanza: 3020

Biografia

Pietro Invernizzi received his MD in July 1993 from the University of Milan, Italy. His clinical and scientific activities began in 1993 and in December 1996 he received his PhD in Gastroenterology from the University of Milan. He spent most of his PhD program period as a research fellow at the Clinical Mass Spectrometry, Children’s Hospital Medical Center, Cincinnati, OH, USA. In 2000 he completed his 4-years training in Gastroenterology at the University of Milan and was licensed as a gastroenterology specialist, and from 2000 to 2008 he had an appointment as Clinical Assistant at the Division of Internal Medicine and Liver Unit of the San Paolo Hospital School of Medicine of the University of Milan. From 2008 to 2015 Dr. Invernizzi is head of the Center for Autoimmune Liver Diseases, Humanitas Clinical and Research Center, Rozzano (Milan), Italy. From 2007 to 2016 he also had an appointment as Assistant Professor at the Department of Internal Medicine, Division of Rheumatology, Allergy, and Clinical Immunology, School of Medicine, University of California at Davis, CA, USA. From December 2015 Dr Invernizzi is Professor in Gastroenterology, University of Milano-Bicocca (Full Professor from September 2020) and from December 2016 chief of the Division of Gastroenterology and Center for Autoimmune Liver Diseases at the San Gerardo Hospital, Monza, Italy. Dr. Invernizzi has co-authored 322 original publications in peer-reviewed journals with a total citations of 13.245, H index 62. Dr. Invernizzi’s articles have included publications in leading scientific journals such as New England Journal of Medicine, Nature Genetics, The Lancet, Ann Intern Med, Gastroenterology, Journal of Hepatology, Hepatology, and J Immunol. Dr. Invernizzi has authored 28 book’s chapters. Dr. Invernizzi’s areas of scientific expertise are on liver diseases, in particular on rare autoimmune liver diseases such as primary biliary cirrhosis (PBC), primary sclerosing cholangitis (PSC), autoimmune hepatitis (AIH), and their overlaps. More recently he extended his interests on the biliary and neuroendocrine tumors.

Pubblicazioni

  • Ciardullo, S., Mantovani, A., Morieri, M., Muraca, E., Invernizzi, P., Perseghin, G. (2024). Impact of MASLD and MetALD on clinical outcomes: A meta-analysis of preliminary evidence. LIVER INTERNATIONAL [10.1111/liv.15939]. Dettaglio

  • Ciardullo, S., Muraca, E., Vergani, M., Invernizzi, P., Perseghin, G. (2024). Advancements in pharmacological treatment of NAFLD/MASLD: a focus on metabolic and liver-targeted interventions. GASTROENTEROLOGY REPORT, 12, 1-10 [10.1093/gastro/goae029]. Dettaglio

  • Cristoferi, L., Porta, M., Bernasconi, D., Leonardi, F., Gerussi, A., Mulinacci, G., et al. (2023). A quantitative MRCP-derived score for medium-term outcome prediction in primary sclerosing cholangitis. DIGESTIVE AND LIVER DISEASE, 55(3 (March 2023)), 373-380 [10.1016/j.dld.2022.10.015]. Dettaglio

  • Kondili, L., Quaranta, M., Cavalletto, L., Calvaruso, V., Ferrigno, L., D'Ambrosio, R., et al. (2023). Profiling the risk of hepatocellular carcinoma after long-term HCV eradication in patients with liver cirrhosis in the PITER cohort. DIGESTIVE AND LIVER DISEASE, 55(7), 907-917 [10.1016/j.dld.2023.01.153]. Dettaglio

  • Ciardullo, S., Carbone, M., Invernizzi, P., Perseghin, G. (2023). Noninvasive identification of probable fibrotic nonalcoholic steatohepatitis across the spectrum of glucose tolerance in the United States. DIABETES RESEARCH AND CLINICAL PRACTICE, 199(May 2023) [10.1016/j.diabres.2023.110679]. Dettaglio

Progetti di ricerca

Dipartimento di Eccellenza 2023-2027
Anno: 2023
Applied Liver cell-BAsed therapy: a randomized controlled trial of epithelial cell adhesion molecule (EpCAM) positive liver cell therapy in end-stage liver disease and refined experimental models of liver regenerative medicine
Anno: 2022
Bando: FAQC 2022 - prima finestra
Enti finanziatori: Università degli Studi di MILANO-BICOCCA
HEAL ITALIA HEALTH EXTENDED ALLIANCE FOR INNOVATIVE THERAPIES, ADVANCED LAB-RESEARCH, AND INTEGRATED APPROACHES OF PRECISION MEDICINE - PE0000019-PNRR per la Missione 4, componente 2 - Avviso 341/2022
Anno: 2022
Bando: Avviso pubblico per la presentazione di Proposte di intervento per la creazione di “Partenariati estesi alle università, ai centri di ricerca, alle aziende per il finanziamento di progetti di ricerca di base” – nell’ambito del Piano Nazionale di Ripresa e
Enti finanziatori: MINISTERO DELL'UNIVERSITA' E DELLA RICERCA (MUR)
INVERNIZZI-Fondo per il finanziamento delle attività base di ricerca
Anno: 2017
Bando: FFABR 2017
Enti finanziatori: M.I.U.R. - MINISTERO DELL'ISTRUZIONE, DELL'UNIVERSITA' E DELLA RICERCA - UFFICIO I - Bilancio e Contabilita'. Coordinamento staff della Direzione
Role of auto-reactive hepatic Natural Killer cells in the pathogensis of Primary Biliary Cholangitis
Anno: 2016
Bando: 2016-027 - Ricerca Finalizzata 2016, Ricerca finalizzata Anno 2016
Enti finanziatori: MINISTERO DELLA SALUTE

Premi e responsabilità scientifiche

Incarichi di insegnamento o ricerca

  • Professore a contratto - Medicina Interna - Università degli Studi di MILANO, 2008